Neurocrine begins phase 1 trial of obesity drug targeting new mechanism

May 4, 2026 7:30 AM

Neurocrine Biosciences Inc. (NASDAQ: NBIX) has initiated a Phase 1 clinical study of NBIP-2118, an investigational obesity treatment that targets ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found